|
Glioma
|
0.500 |
Biomarker
|
disease |
BEFREE |
In the present study, we confirmed that lncRNA SNHG16 was highly expressed in glioma and may exert oncogenic function as a competing endogenous RNA (ceRNA) to regulate EGFR by sponging of miR-373-3p through activating PI3K/AKT pathway, which providing a new insight of the regulatory network of lncRNA SNHG16 in the development of glioma.
|
31226483 |
2020 |
|
Glioma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Glioma Stem Cell-Specific Superenhancer Promotes Polyunsaturated Fatty-Acid Synthesis to Support EGFR Signaling.
|
31201181 |
2019 |
|
Glioma
|
0.500 |
Biomarker
|
disease |
BEFREE |
To establish a whole-animal approach that can be used to readily identify individual pathometabolic signaling factors, we induced glioma formation in the adult Drosophila brain by activating the EGFR-PI3K pathway.
|
30357574 |
2019 |
|
Glioma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
In our work, we explored the optimized preparation of [<sup>89</sup>Zr]Zr-DFO-nimotuzumab, and evaluated <sup>89</sup>Zr-labeled monoclonal antibody (mAb) construct for targeted imaging of epidermal growth factor receptor (EGFR) overexpressed in glioma.
|
30826708 |
2019 |
|
Glioma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Subsequent cell recovery experiment indicated that microRNA-374b and EGFR had a mutual regulation and could affect the malignant progression of glioma all together.
|
31173297 |
2019 |
|
Glioma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
<b>Conclusions</b>: We demonstrate that the protein expression of EGFR in serum EVs is an effective diagnostic marker of glioma.
|
31410219 |
2019 |
|
Glioma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
rLTL was measured by qPCR in a Swedish population-based glioma case-control cohort (421 cases and 671 controls). rLTL was related to glioma risk and health parameters associated with asthma and allergy, as well as molecular events in glioma including IDH1 mutation, 1p/19q co-deletion, and EGFR amplification.
|
30560391 |
2019 |
|
Glioma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Here we revealed that EGFR mutation leads to an up-regulation of immune response related pathways and dismal prognosis in lower-grade glioma.
|
31801484 |
2019 |
|
Glioma
|
0.500 |
Biomarker
|
disease |
BEFREE |
We discovered a previously unknown major resistance mechanism in glioma in that most EGFR domain III-targeting antibodies do not neutralize EGFRvIII.
|
31002307 |
2019 |
|
Glioma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Epidermal growth factor receptor (EGFR) is associated with the progression of a wide range of cancers including breast, glioma, lung, and liver cancer.
|
31546749 |
2019 |
|
Glioma
|
0.500 |
Biomarker
|
disease |
BEFREE |
EGFR was significantly associated with all glioma and glioblastoma in males only and a female-specific association in TERT, all of which remained nominally significant after conditioning on known risk loci.
|
30124908 |
2019 |
|
Glioma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Mechanistically, we uncovered that BCAR4 activated PI3K/AKT signaling pathway in glioma through upregulating EGFR and interacting with it.
|
31173355 |
2019 |
|
Glioma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Here we use this <i>Drosophila</i> glioma model to identify death-associated protein kinase (Drak), a cytoplasmic serine/threonine kinase orthologous to the human kinase STK17A, as a downstream effector of EGFR and PI3K signaling pathways.
|
30530503 |
2019 |
|
Glioma
|
0.500 |
Biomarker
|
disease |
BEFREE |
EGFR-targeted therapy might be an effective treatment for glioma.
|
31673738 |
2019 |
|
Glioma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We aimed to explore the prognostic impact of epidermal growth factor receptor copy number gain (EGFR CN gain), one of the most common genetic alterations in IDH-WT glioma, in young adults with IDH-WT GBM.
|
31542863 |
2019 |
|
Glioma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The ErbB family of proteins, structurally related to the epidermal growth factor receptor (EGFR), is found to be overexpressed in many cancers such as gliomas, a lung and cervical carcinomas.
|
30970212 |
2019 |
|
Glioma
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
Overall, GALNT2 facilitates the malignant characteristics of glioma by influencing the O-glycosylation and phosphorylation of EGFR and the subsequent downstream PI3K/Akt/mTOR axis.
|
31076460 |
2019 |
|
Glioma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
EGFRvIII is a unique EGFR mutant subtype in glioma, and the CRISPR-Cas13a system induces death in EGFRvIII-overexpressing glioma cells.
|
31637166 |
2019 |
|
Glioma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Dacomitinib inhibited cell viability and proliferation of epidermal growth factor receptor (<i>EGFR</i>)-amplified glioma.
|
30782784 |
2019 |
|
Glioma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The pipeline was applied to glioma scRNA-seq data and revealed a tumor-associated microglia/macrophage-mediated EGFR/ERBB2 feedback-crosstalk signaling module, which was defined as a multilayer network biomarker (MNB) to predict survival outcome and therapeutic response of glioma patients.
|
31329830 |
2019 |
|
Glioma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Then, we also analyzed the impact of TERT promoter mutations, PTEN deletion, EGFR amplification and MGMT promoter methylation in diagnosis, prognosis and response to therapy in glioma molecular subgroup.
|
31623593 |
2019 |
|
Glioma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The growth of established EGFR- or EGFRvIII-overexpressing glioma xenografts was suppressed by M27-28BBZ CAR T cells as well.
|
30201736 |
2018 |
|
Glioma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Epidermal growth factor receptor promotes glioma progression by regulating xCT and GluN2B-containing N-methyl-d-aspartate-sensitive glutamate receptor signaling.
|
30298963 |
2018 |
|
Glioma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Here we analyzed the impact of EGFRvIII on the profile of glioma EVs using isogenic tumor cell lines, in which this oncogene exhibits a strong transforming activity.
|
30006486 |
2018 |
|
Glioma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Uptake kinetics of EGFR-targeted fluorescent Affibody (ABY-029) were studied with a view toward optimizing efficacy of tumor detection in a glioma as a function of both delivered dose and concurrent administration of unlabeled cetuximab (an EGFR antagonist).
|
30129069 |
2018 |